HTG Molecular Diagnostics

company

About

HTG Molecular Diagnostics develops assays and reagent systems for gene expression analysis.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$10M
Industries
Biotechnology,Genetics,Health Diagnostics,Life Science,Medical
Founded date
Jan 1, 1997
Number Of Employee
51 - 100
Operating Status
Active
Stock Symbol
nasdaq:HTGM
Legal Name
HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications.

The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profile hundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach.

HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
15
$159.50M
HTG Molecular Diagnostics has raised a total of $159.50M in funding over 2 rounds. Their latest funding was raised on Dec 21, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 21, 2022 Post-IPO Equity $10M Detail
Mar 18, 2022 Post-IPO Equity $7.50M Detail
Oct 3, 2019 Post-IPO Equity $22.50M Detail
Apr 28, 2015 IPO $53M Detail
Aug 29, 2014 Debt Financing $16M 2 Detail

Investments

Number of Investments
Number of Lead Investments
5
0
HTG Molecular Diagnostics has made 5 investments. Their most recent investment was on Nov 30, 2022, when ResortPass raised $26M.
Date Company Name
Round Money Raised Industry Lead Investor
Nov 30, 2022 ResortPass
Series B $26M Hospitality
Feb 1, 2022 OLIPOP
Series B $30M Food and Beverage
Dec 15, 2021 Forethought
Series C $65M Artificial Intelligence
Nov 22, 2021 MoonPay
Series A $555M Financial Services
Jun 8, 2017 Daily Harvest
Series A E-Commerce

Investors

Number of Lead Investors
Number of Investors
1
11
HTG Molecular Diagnostics is funded by 11 investors. SR One and Oxford Finance LLC are the most recent investors.
Investor Name Lead Investor Funding Round
SR One Yes Series D
Oxford Finance LLC Debt Financing
Silicon Valley Bank Debt Financing
Fletcher Spaght, Inc. Series D
Merck Capital Ventures Series D
Novo Holdings Series D
Solstice Capital Series D
Valley Ventures Series D
Emerging Technology Partners Series B
Village Ventures Series B

Employee Profiles

Number of Employee Profiles
19
HTG Molecular Diagnostics has 19 current employee profiles, including Executive Shaun McMeans
Executive
Advisor
Board member
Board member
Advisor